Format

Send to

Choose Destination
  • Showing results for a modified search because your search retrieved no results.
Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):214-222. doi: 10.1016/j.numecd.2019.09.023. Epub 2019 Oct 11.

Association between dairy product consumption and hyperuricemia in an elderly population with metabolic syndrome.

Author information

1
Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, IISPV, Hospital Universitari Sant Joan de Reus, Spain; CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
2
Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, IISPV, Hospital Universitari Sant Joan de Reus, Spain; CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: nancy.babio@urv.cat.
3
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
4
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Preventive Medicine, University of Valencia, Valencia, Spain.
5
Cardiovascular Risk and Nutrition research group (CARIN), Hospital del Mar Research Institute (IMIM), Barcelona, Spain; Blanquerna, School of Health Sciences, Universitat Ramon Llull, Barcelona, Spain.
6
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Clinical Epidemiology and Public Health Department, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
7
CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; Miguel Hernandez University, ISABIAL-FISABIO, Alicante, Spain.
8
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, Organización Sanitaria Integrada (OSI) ARABA, University Hospital Araba, Vitoria-Gasteiz, Spain.
9
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Nursing, School of Health Sciences, University of Málaga-IBIMA, Málaga, Spain.
10
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University of Navarra, Department of Nutrition, Food Science and Physiology, IDISNA, Pamplona, Spain; Institute of Biomedicine (IBIOMED), University of León, León, Spain.
11
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University of Las Palmas de Gran Canaria, Research Institute of Biomedical and Health Sciences (IUIBS), Preventive Medicine Service, Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, Las Palmas, Spain.
12
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Internal Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.
13
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Virgen de la Victoria Hospital, Department of Endocrinology, University of Málaga, Málaga, Spain.
14
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain.
15
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
16
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, Palma de Mallorca, Spain.
17
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.
18
CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; Department of Preventive Medicine, University of Granada, Granada, Spain.
19
CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; Departamento de Ciencias de la Salud, Centro de Estudios Avanzados en Olivar y Aceites de Oliva, Universidad de Jaén, Jaén, Spain.
20
Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
21
Nutritional Genomics and Epigenomics Group, IMDEA Food, CEI UAM + CSIC, Madrid, Spain.
22
Institute of Biomedicine (IBIOMED), University of León, León, Spain; CIBER Diabetes y enfermedades Metabólicos (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
23
Departament of Endocrinology, IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona, Spain.
24
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Endocrinology, Fundación Jiménez-Díaz, Madrid, Spain.
25
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain.
26
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, Pamplona, Spain.
27
Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, IISPV, Hospital Universitari Sant Joan de Reus, Spain.
28
Cardiovascular Risk and Nutrition research group (CARIN), Hospital del Mar Research Institute (IMIM), Barcelona, Spain.
29
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Unidad Gestión Clínica de Torrequebrada, Distrito Atención Primaria Costa del Sol, Servicio Andaluz de Salud, Spain.
30
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University of Navarra, Department of Nutrition, Food Science and Physiology, IDISNA, Pamplona, Spain.
31
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Cardiovascular Risk and Nutrition research group (CARIN), Hospital del Mar Research Institute (IMIM), Barcelona, Spain; Department of Medicine, Universitat Autonoma de Barcelona, Endocrinology Unit, Hospital del Mar, Barcelona, Spain.
32
CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Cardiovascular Risk and Nutrition research group (CARIN), Hospital del Mar Research Institute (IMIM), Barcelona, Spain.
33
Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, IISPV, Hospital Universitari Sant Joan de Reus, Spain; CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: jordi.salas@urv.cat.

Abstract

BACKGROUND AND AIMS:

The prevalence of hyperuricemia has increased substantially in recent decades. It has been suggested that it is an independent risk factor for weight gain, hypertension, hypertriglyceridemia, metabolic syndrome (MetS), and cardiovascular disease. Results from epidemiological studies conducted in different study populations have suggested that high consumption of dairy products is associated with a lower risk of developing hyperuricemia. However, this association is still unclear. The aim of the present study is to explore the association of the consumption of total dairy products and their subtypes with the risk of hyperuricemia in an elderly Mediterranean population with MetS.

METHODS AND RESULTS:

Baseline cross-sectional analyses were conducted on 6329 men/women (mean age 65 years) with overweight/obesity and MetS from the PREDIMED-Plus cohort. Dairy consumption was assessed using a food frequency questionnaire. Multivariable-adjusted Cox regressions were fitted to analyze the association of quartiles of consumption of total dairy products and their subtypes with the prevalence of hyperuricemia. Participants in the upper quartile of the consumption of total dairy products (multiadjusted prevalence ratio (PR) = 0.84; 95% CI: 0.75-0.94; P-trend 0.02), low-fat dairy products (PR = 0.79; 95% CI: 0.70-0.89; P-trend <0.001), total milk (PR = 0.81; 95% CI: 0.73-0.90; P-trend<0.001), low-fat milk (PR = 0.80; 95% CI: 0.72-0.89; P-trend<0.001, respectively), low-fat yogurt (PR = 0.89; 95% CI: 0.80-0.98; P-trend 0.051), and cheese (PR = 0.86; 95% CI: 0.77-0.96; P-trend 0.003) presented a lower prevalence of hyperuricemia. Whole-fat dairy, fermented dairy, and yogurt consumption were not associated with hyperuricemia.

CONCLUSIONS:

High consumption of total dairy products, total milk, low-fat dairy products, low-fat milk, low-fat yogurt, and cheese is associated with a lower risk of hyperuricemia.

KEYWORDS:

Cheese; Dairy products; Hyperuricemia; Milk; Yogurt

Conflict of interest statement

Declaration of Competing Interest Mena-Sánchez G declares no conflicts of interest. Babio N declares that she has received payments from Danone S.A. for scientific and technical consulting but not for the preparation of this study. She is one of the members of the Scientific Advisory Board of the EU program for the promotion of milk and milk products within the framework of appropriate dietary practices. Becerra-Tomás N declares no conflicts of interest. Miguel Ángel Martínez-González, Andrés Díaz-López, Dolores Corella, Maria Dolores Zomeño, Dora Romaguera, Jesús Vioque, Ángel M. Alonso-Gómez, Julia Wärnberg, J. Alfredo Martínez, Luís Serra-Majem, Ramon Estruch, Rosa Bernal, José Lapetra, Xavier Pintó, Josep A. Tur, José Lopez-Miranda, Naomi Cano-Ibáñez, Jose Juan Gaforio, Pilar Matía-Martín, Lidia Daimiel, José Luis Llisterri Caro, Josep Vidal, Clotilde Vázquez, Emili Ros, Ana Garcia Arellano, Antoni Palau, Rebeca Fernández-Carrión, Alejandra Pérez-Vega, Marga Morey, Manoli García de la Hera, Jessica Vaquero-Luna, Francisco J. Carmona-González, Itziar Abete, Jacqueline Álvarez-Pérez, Rosa Casas, José Carlos Fernández-García, José Manuel Santos-Lozano, Emili Corbella, Antoni Sureda, Miguel Ruiz Canela, Rocio Barragán, Albert Goday, Marian Martín, María Consuelo Altozano Rodado, Estefanía Toledo, Montse Fitó declare no conflicts of interest. Salas-Salvadó J reports that he has served on the Board of and received grant support through his institution from the International Nut and Dried Fruit Council; has served as a member of the Danone S.A. Advisory Board; has received personal consulting fees from Danone, Font Vella Lanjaron, Nuts for Life, and Eroski; and has received grant support through his institution from the Nut and Dried Fruit Foundation and Eroski.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center